
(Bloomberg) — The University of Oxford and AstraZeneca Plc have restarted a U.K. trial of an experimental Covid-19 vaccine after it was halted over concerns about a participant who fell ill. The U.K. Medicines Health Regulatory Authority recommended that the study resume after an independent review of the safety data triggered a pause on Sept. 6, Oxford said in a statement. It declined to disclose details about the volunteer’s illness. While…
More Stories
Record Korean Cases; Trader’s Guide to Rollout: Virus Update
California Hits Record; Trader’s Guide to Rollout: Virus Update
AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push